Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita, +22

New England Journal of Medicine

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy, +14

Journal of Clinical Oncology

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito, +14

The Lancet Oncology

Breast OncologyOncologyMedicineImmunologyAdvanced Breast +8

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura, Junji Tsurutani, Shunji Takahashi, +14

The Lancet Oncology

Breast OncologyOncologyBreast CancerPharmacotherapyCancer Treatment +4

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Guy Jérusalem, Yeon Hee Park, Toshinari Yamashita, +16

Cancer Discovery

Gravitraps for Management of Dengue Clusters in Singapore

Caleb Lee, Indra Vythilingam, Chee‐Seng Chong, +5

American Journal of Tropical Medicine and Hygiene

Vector-borne PathogenVector ManagementDengue ClustersGlobal HealthEntomology +8

Efficacy of Wolbachia-mediated sterility to reduce the incidence of dengue: a synthetic control study in Singapore

Jue Tao Lim, Somya Bansal, Chee‐Seng Chong, +11

The Lancet Microbe

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita, +23

Cancer Research

Abstract Background TrastuzumabBreast OncologyMedian DurationMedicineImmunology +13

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03

Sara A. Hurvitz, Sung‐Bae Kim, Wei‐Pang Chung, +17

Cancer Research

Breast OncologyImmunologyPathologyImmunotherapeuticsStudy Destiny-breast03 +16

Gravitrap deployment for adult Aedes aegypti surveillance and its impact on dengue cases

Janet Ong, Chee‐Seng Chong, Grace Yap, +4

PLoS neglected tropical diseases